These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

66 related articles for article (PubMed ID: 28292959)

  • 1. Multiepitope tissue analysis reveals SPPL3-mediated ADAM10 activation as a key step in the transformation of melanocytes.
    Ostalecki C; Lee JH; Dindorf J; Collenburg L; Schierer S; Simon B; Schliep S; Kremmer E; Schuler G; Baur AS
    Sci Signal; 2017 Mar; 10(470):. PubMed ID: 28292959
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of BRAF mutation and p53 inactivation during transformation of a subpopulation of primary human melanocytes.
    Yu H; McDaid R; Lee J; Possik P; Li L; Kumar SM; Elder DE; Van Belle P; Gimotty P; Guerra M; Hammond R; Nathanson KL; Dalla Palma M; Herlyn M; Xu X
    Am J Pathol; 2009 Jun; 174(6):2367-77. PubMed ID: 19389934
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CDKN2B Loss Promotes Progression from Benign Melanocytic Nevus to Melanoma.
    McNeal AS; Liu K; Nakhate V; Natale CA; Duperret EK; Capell BC; Dentchev T; Berger SL; Herlyn M; Seykora JT; Ridky TW
    Cancer Discov; 2015 Oct; 5(10):1072-85. PubMed ID: 26183406
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BRAF mutations are sufficient to promote nevi formation and cooperate with p53 in the genesis of melanoma.
    Patton EE; Widlund HR; Kutok JL; Kopani KR; Amatruda JF; Murphey RD; Berghmans S; Mayhall EA; Traver D; Fletcher CD; Aster JC; Granter SR; Look AT; Lee C; Fisher DE; Zon LI
    Curr Biol; 2005 Feb; 15(3):249-54. PubMed ID: 15694309
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PAX2 regulates ADAM10 expression and mediates anchorage-independent cell growth of melanoma cells.
    Lee SB; Doberstein K; Baumgarten P; Wieland A; Ungerer C; Bürger C; Hardt K; Boehncke WH; Pfeilschifter J; Mihic-Probst D; Mittelbronn M; Gutwein P
    PLoS One; 2011; 6(8):e22312. PubMed ID: 21876729
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Distribution of BRAF T1799A(V600E) mutations across various types of benign nevi: implications for melanocytic tumorigenesis.
    Wu J; Rosenbaum E; Begum S; Westra WH
    Am J Dermatopathol; 2007 Dec; 29(6):534-7. PubMed ID: 18032947
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunohistochemical analysis of BRAF(V600E) expression of primary and metastatic melanoma and comparison with mutation status and melanocyte differentiation antigens of metastatic lesions.
    Busam KJ; Hedvat C; Pulitzer M; von Deimling A; Jungbluth AA
    Am J Surg Pathol; 2013 Mar; 37(3):413-20. PubMed ID: 23211290
    [TBL] [Abstract][Full Text] [Related]  

  • 8. C-Raf inhibits MAPK activation and transformation by B-Raf(V600E).
    Karreth FA; DeNicola GM; Winter SP; Tuveson DA
    Mol Cell; 2009 Nov; 36(3):477-86. PubMed ID: 19917255
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Near-genomewide RNAi screening for regulators of BRAF(V600E) -induced senescence identifies RASEF, a gene epigenetically silenced in melanoma.
    Kaplon J; Hömig-Hölzel C; Gao L; Meissl K; Verdegaal EM; van der Burg SH; van Doorn R; Peeper DS
    Pigment Cell Melanoma Res; 2014 Jul; 27(4):640-52. PubMed ID: 24703243
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Exploration of genetic alterations in human endometrial cancer and melanoma: distinct tumorigenic pathways that share a frequent abnormal PI3K/AKT cascade.
    Ogawa K; Sun C; Horii A
    Oncol Rep; 2005 Dec; 14(6):1481-5. PubMed ID: 16273242
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumor-derived fibronectin is involved in melanoma cell invasion and regulated by V600E B-Raf signaling pathway.
    Gaggioli C; Robert G; Bertolotto C; Bailet O; Abbe P; Spadafora A; Bahadoran P; Ortonne JP; Baron V; Ballotti R; Tartare-Deckert S
    J Invest Dermatol; 2007 Feb; 127(2):400-10. PubMed ID: 16960555
    [TBL] [Abstract][Full Text] [Related]  

  • 12. c-Kit mutants require hypoxia-inducible factor 1alpha to transform melanocytes.
    Monsel G; Ortonne N; Bagot M; Bensussan A; Dumaz N
    Oncogene; 2010 Jan; 29(2):227-36. PubMed ID: 19802003
    [TBL] [Abstract][Full Text] [Related]  

  • 13. BRAF inhibitor therapy-associated melanocytic lesions lack the BRAF V600E mutation and show increased levels of cyclin D1 expression.
    Mudaliar K; Tetzlaff MT; Duvic M; Ciurea A; Hymes S; Milton DR; Tsai KY; Prieto VG; Torres-Cabala CA; Curry JL
    Hum Pathol; 2016 Apr; 50():79-89. PubMed ID: 26997441
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reversal of melanocytic malignancy by keratinocytes is an E-cadherin-mediated process overriding beta-catenin signaling.
    Li G; Fukunaga M; Herlyn M
    Exp Cell Res; 2004 Jul; 297(1):142-51. PubMed ID: 15194432
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increased expression of germinal center-associated nuclear protein (GANP) is associated with malignant transformation of melanocytes.
    Kageshita T; Kuwahara K; Oka M; Ma D; Ono T; Sakaguchi N
    J Dermatol Sci; 2006 Apr; 42(1):55-63. PubMed ID: 16431081
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Human melanoma cells expressing V600E B-RAF are susceptible to IGF1R targeting by small interfering RNAs.
    Yeh AH; Bohula EA; Macaulay VM
    Oncogene; 2006 Oct; 25(50):6574-81. PubMed ID: 16715137
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oncogenic B-Raf(V600E) induces spindle abnormalities, supernumerary centrosomes, and aneuploidy in human melanocytic cells.
    Cui Y; Borysova MK; Johnson JO; Guadagno TM
    Cancer Res; 2010 Jan; 70(2):675-84. PubMed ID: 20068179
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Detection of the BRAF V600E mutation in melanocytic lesions using the ligase detection reaction.
    Turner DJ; Zirvi MA; Barany F; Elenitsas R; Seykora J
    J Cutan Pathol; 2005 May; 32(5):334-9. PubMed ID: 15811117
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oncogenic BRAF signalling increases Mcl-1 expression in cutaneous metastatic melanoma.
    McKee CS; Hill DS; Redfern CP; Armstrong JL; Lovat PE
    Exp Dermatol; 2013 Nov; 22(11):767-9. PubMed ID: 24118207
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BRAF and NRAS mutations in melanoma and melanocytic nevi.
    Poynter JN; Elder JT; Fullen DR; Nair RP; Soengas MS; Johnson TM; Redman B; Thomas NE; Gruber SB
    Melanoma Res; 2006 Aug; 16(4):267-73. PubMed ID: 16845322
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.